Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Elderly Patients with Advanced Non-Small Cell Lung Cancer

Table 1

Main studies on EGFR TKIs for elderly (≥70 years) patients with advanced NSCLC.

Author	Study arm	No. of patients	Response rate (%)	Median OS (months)
Shepherd* et al. [31]	Erlotinib versus	112	8	7.6
	Placebo	50	0	5.0
Wheatley-Price^§ et al. [32]	Erlotinib	80	10	10.9
Crinò^§ et al. [29]	Gefitinib versus	99	3.1	5.9
	Vinorelbine	97	5.1	8.0

^∗2nd or 3rd -line; ^§first -line.